Overview
Despite the impact of COVID-19 on most medical device markets, global sales of mechanical thrombectomy devices for the emergency treatment of acute ischemic stroke (AIS) - which includes both stent retrievers and aspiration devices and associated products - is expected to increase at a healthy CAGR of approximately 5.7%, from nearly $677m in 2019 to an estimated $894m in 2024.
Stent retrievers contribute approximately 60% of sales; however, aspiration devices remain a valid option and are also exhibiting solid growth, complementing stent retrievers in ensuring complete clot removal.
Next-generation stent retriever devices include innovative designs that improve clot capture and allow for more atraumatic clot removal from selected vessels in the brain (large vessel occlusion/LVO of the internal carotid artery or proximal middle cerebral artery).
Solid clinical evidence for mechanical thrombectomy, particularly stent retrievers, has been established supporting superior clinical outcomes and use as a supplemental therapy to the first line of thrombolytic medication therapy - intravenous recombinant tissue plasminogen activator (IV r-tPA) - when tPA fails or is not an option to re-establish blood flow in the brain. The goal of more comprehensive medication plus mechanical thrombectomy therapy is to rescue cells in the penumbra before further irreversible ischemic injury occurs that often results in severe disability or death.
Key competitors in the mechanical thrombectomy devices market include five major medical devices companies and one startup: Medtronic, Penumbra, Stryker, Cerenovus/Johnson & Johnson, MicroVention/Terumo, and Rapid Medical.
This medical device market and technology report provides:
Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2019-24 time period.
Despite the impact of COVID-19 on most medical device markets, global sales of mechanical thrombectomy devices for the emergency treatment of acute ischemic stroke (AIS) - which includes both stent retrievers and aspiration devices and associated products - is expected to increase at a healthy CAGR of approximately 5.7%, from nearly $677m in 2019 to an estimated $894m in 2024.
Stent retrievers contribute approximately 60% of sales; however, aspiration devices remain a valid option and are also exhibiting solid growth, complementing stent retrievers in ensuring complete clot removal.
Next-generation stent retriever devices include innovative designs that improve clot capture and allow for more atraumatic clot removal from selected vessels in the brain (large vessel occlusion/LVO of the internal carotid artery or proximal middle cerebral artery).
Solid clinical evidence for mechanical thrombectomy, particularly stent retrievers, has been established supporting superior clinical outcomes and use as a supplemental therapy to the first line of thrombolytic medication therapy - intravenous recombinant tissue plasminogen activator (IV r-tPA) - when tPA fails or is not an option to re-establish blood flow in the brain. The goal of more comprehensive medication plus mechanical thrombectomy therapy is to rescue cells in the penumbra before further irreversible ischemic injury occurs that often results in severe disability or death.
Key competitors in the mechanical thrombectomy devices market include five major medical devices companies and one startup: Medtronic, Penumbra, Stryker, Cerenovus/Johnson & Johnson, MicroVention/Terumo, and Rapid Medical.
This medical device market and technology report provides:
- overview of stroke, diagnosis, and treatment
- mechanical thrombectomy technologies, leading products, and features
- emerging technologies/pipelines and innovations
- in-depth market and competitive analyses, including market drivers/limiters, 5-year market forecasts by segment and region, and global/regional market share
- overview of companies, financials, and strategic growth plans
Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2019-24 time period.
Table of Contents
Executive Summary
1. Clinical Overview
2. Mechanical Thrombectomy Devices for Acute Ischemic Stroke
3. Market Analysis
List of Exhibits
